Gene Universal Inc.

geneuniversal.com

Gene Universal, located in Delaware USA, is a pioneer in the field of gene synthesis and synthetic biology. As a leading company in genomics research and applied biological technology, and with our strong technical force, unparalleled customized service and fast delivery time, we are aiming to provide more cost-effective service and product to accelerate the global research in drug discovery, biology optimization, food and agriculture, etc. Gene Universal is specialized in the area of genetic engineering, biosystem engineering and synthetic biology. By providing our industrialized and highly intensive gene synthesis platform, we could deliver both normal and complex genes in short promised time. We have also developed sophisticated software programs to design and optimize complex gene libraries and genetic systems, with these bioinformatics tools and our high-efficiency production management systems, we are able to satisfy scientific researchers with high-efficient, low-cost, and large-scale synthetic genes and genome DNA.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

DEBIOPHARM ANNOUNCES FIRST PATIENT DOSED IN INVESTIGATOR-INITIATED, RANDOMIZED PHASE II, OPEN-LABEL CLINICAL TRIAL FOR ITS ANTIVIRAL ALISPORIVIR

Debiopharm | January 18, 2021

news image

Debiopharm , a Swiss biopharmaceutical organization, reported the principal patient dosed in a investigator-initiated, randomized phase II, open-label clinical trial for its antiviral alisporivir (Debio 025). The examination will be led by the AP-HP to assess the adequacy and wellbeing of the cyclophilin inhibitor in the therapy of beginning phase, hospitalized COVID-19 patients who don't need clinical ventilation and have not shown indications of intense respiratory distress syndrome. The e...

Read More

Medical

RATIO THERAPEUTICS LAUNCHES TO DISCOVER AND DRIVE EARLY CLINICAL DEVELOPMENT OF BEST-IN-CLASS TARGETED RADIOPHARMACEUTICALS FOR TREATMENT OF CANCERS

Ratio Therapeutics | June 13, 2022

news image

Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted radiopharmaceuticals for the treatment of cancers. Founded by entrepreneurial scientists Jack Hoppin, Ph.D., and John Babich, Ph.D., Ratio emerges from stealth mode with more than $20 million in seed funding, fully funded development alliances with Bayer AG and Lantheus Holdings Inc., a robust portfolio of assets developed with two proprietary technologies, and a growing team of world-class expert...

Read More

Medical

KINTOR PHARMA PROVIDES UPDATE ON ONE OF ITS THREE MULTI-REGIONAL PHASE 3 TRIALS OF PROXALUTAMIDE FOR COVID-19

Kintor Pharma | December 29, 2021

news image

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, provided an update on its multi-regional study of proxalutamide for the treatment of COVID-19 infection. Statistical criteria were not met at an interim analysis of the phase III outpatient study, designed for testing efficacy and safety of proxalutamide for treating COVID-19 in non-hospitalized COVID-19 patients. At the interim analysis, 348 patients with mild-...

Read More

MedTech

PANGIA BIOTECH PLANS EXPANDED MULTI-CANCER EARLY DETECTION LIQUID BIOPSY STUDY

PanGIA Biotech, Inc. | January 05, 2024

news image

PanGIA Biotech, a US based biotechnology company with a mission to develop true liquid biopsy technology that is scalable for global impact, today announced that it is finalizing its three-year, prospective, multicenter, clinical study on prostate cancer liquid biopsy. This announcement comes as the company prepares to launch additional clinical studies in multi-cancer early detection using the PanGIA® Liquid Biopsy Platform. “The PanGIA urine based true liquid biopsy technology ...

Read More
news image

Medical

DEBIOPHARM ANNOUNCES FIRST PATIENT DOSED IN INVESTIGATOR-INITIATED, RANDOMIZED PHASE II, OPEN-LABEL CLINICAL TRIAL FOR ITS ANTIVIRAL ALISPORIVIR

Debiopharm | January 18, 2021

Debiopharm , a Swiss biopharmaceutical organization, reported the principal patient dosed in a investigator-initiated, randomized phase II, open-label clinical trial for its antiviral alisporivir (Debio 025). The examination will be led by the AP-HP to assess the adequacy and wellbeing of the cyclophilin inhibitor in the therapy of beginning phase, hospitalized COVID-19 patients who don't need clinical ventilation and have not shown indications of intense respiratory distress syndrome. The e...

Read More
news image

Medical

RATIO THERAPEUTICS LAUNCHES TO DISCOVER AND DRIVE EARLY CLINICAL DEVELOPMENT OF BEST-IN-CLASS TARGETED RADIOPHARMACEUTICALS FOR TREATMENT OF CANCERS

Ratio Therapeutics | June 13, 2022

Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted radiopharmaceuticals for the treatment of cancers. Founded by entrepreneurial scientists Jack Hoppin, Ph.D., and John Babich, Ph.D., Ratio emerges from stealth mode with more than $20 million in seed funding, fully funded development alliances with Bayer AG and Lantheus Holdings Inc., a robust portfolio of assets developed with two proprietary technologies, and a growing team of world-class expert...

Read More
news image

Medical

KINTOR PHARMA PROVIDES UPDATE ON ONE OF ITS THREE MULTI-REGIONAL PHASE 3 TRIALS OF PROXALUTAMIDE FOR COVID-19

Kintor Pharma | December 29, 2021

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, provided an update on its multi-regional study of proxalutamide for the treatment of COVID-19 infection. Statistical criteria were not met at an interim analysis of the phase III outpatient study, designed for testing efficacy and safety of proxalutamide for treating COVID-19 in non-hospitalized COVID-19 patients. At the interim analysis, 348 patients with mild-...

Read More
news image

MedTech

PANGIA BIOTECH PLANS EXPANDED MULTI-CANCER EARLY DETECTION LIQUID BIOPSY STUDY

PanGIA Biotech, Inc. | January 05, 2024

PanGIA Biotech, a US based biotechnology company with a mission to develop true liquid biopsy technology that is scalable for global impact, today announced that it is finalizing its three-year, prospective, multicenter, clinical study on prostate cancer liquid biopsy. This announcement comes as the company prepares to launch additional clinical studies in multi-cancer early detection using the PanGIA® Liquid Biopsy Platform. “The PanGIA urine based true liquid biopsy technology ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us